M.D. Anderson Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, M.D. Anderson Cancer Center sits in the top decile of US sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count).
M.D. Anderson Cancer Center: 2,692 sponsored US clinical trials, 549 recruiting.
M.D. Anderson Cancer Center sponsors 2,692 registered US clinical trials on ClinicalTrials.gov, 549 of them currently recruiting, and 1,201 completed. 124 of these trials are in Phase 3-4 (later-stage) and 1,719 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hematopoietic and Lymphoid Cell Neoplasm, with 44 trials.
Top-decile sponsor footprint
M.D. Anderson Cancer Center ranks in the top decile of sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
2,692 total, page 33 of 54
Eltrombopag Olamine in Increasing Platelet Counts in Patients Undergoing Transplant
NCT01927731
Plerixafor for Stem Cell Mobilization in Normal Donors
NCT01818284
Contrast Enhanced Intraoperative Ultrasound for Detection and Characterization of Renal Mass Undergoing Open Partial Nephrectomy
NCT01894607
Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)
NCT01893372
Carfilzomib in Refractory Renal Cell Carcinoma (RCC)
NCT01775930
Hatha Yoga in Lung Cancer Couples
NCT01952860
Text Messages in Preventing Tobacco Use in Young Adults
NCT03457480
A Feasibility Study of Prophylactic White Blood Cell Transfusions
NCT01932710
Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
NCT01900002
Ferumoxytol - Iron Oxide Nanoparticle Magnetic Resonance Dynamic Contrast Enhanced MRI
NCT01895829
Feasibility - Beta Adrenergic Blockade (BB) in Cervical Cancer (CX)
NCT01902966
Intravesical Cidofovir for Hemorrhagic Cystitis
NCT01816646
Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation
NCT01891968
Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors
NCT01751425
Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
NCT01893320
Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor
NCT01603212
Project Impact: A Culturally-Tailored Adherence Intervention for Latino Smokers
NCT01811628
Clinical and Technical Feasibility of a Ultrasuperparamagnetic Nanoparticle Iron Oxide (USPIO)-Enhanced Magnetic Resonance Lymph Node Imaging
NCT01815333
Widespread vs. Selective Screening for Hepatitis B Infection Prior to Chemotherapy
NCT01970254
CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL)
NCT01653717
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies
NCT01823198
Fentanyl Pectin Nasal Spray (FNPS) for Exercise-Induced Breakthrough Dyspnea
NCT01832402
Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma
NCT01729091
An Endometrial Cancer Chemoprevention Study of Metformin
NCT01697566
Glioblastoma Multiforme (GBM) Proton vs. Intensity Modulated Radiotherapy (IMRT)
NCT01854554
Three-Factor Eating Questionnaire in Measuring Eating Behavior in Adolescent and Young Adult Survivors of CNS Tumors
NCT01682824
Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT01664897
Message: Study of Patients' Perception of Physician's Compassion
NCT02357108
An Open-Labeled Pilot Study of Biomarker Response Following Short-Term Exposure to Metformin
NCT01816659
Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma
NCT01827111
Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
NCT01729104
Antimicrobial Catheter Lock Solution for the Treatment of Central Line Associated Bloodstream Infection (CLABSI)
NCT01539343
Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)
NCT01821963
Intervention for Symptom Burden During Maintenance Therapy for Multiple Myeloma
NCT01793051
Best Systemic Therapy or Best Systemic Therapy (BST) Plus Definitive Treatment (Radiation or Surgery)
NCT01751438
Donor Cord Blood T-Cell Infusion After Stem Cell Transplant in Treating Patients With Relapsed Hematological Malignancies
NCT01630564
Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia
NCT01319981
IADAPT-Third Phase
NCT01698762
Dasatinib and Crizotinib in Advanced Cancer
NCT01744652
Ipilimumab and Lenalidomide in Advanced Cancer
NCT01750983
Symptom Burden in Head and Neck Cancer
NCT01219673
Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia
NCT01712308
Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia
NCT01794702
Ipilimumab and Imatinib Mesylate in Advanced Cancer
NCT01738139
Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients
NCT01440582
Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML)
NCT01786343
E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes
NCT01692197
CD5789 in Early Cutaneous T-Cell Lymphoma (CTCL)
NCT01804335
A Phase II Study of Minocycline and Armodafinil for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Esophageal Cancer
NCT01746043
IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma
NCT01409174
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 748 |
| Phase 2 | 971 |
| Phase 3 | 96 |
| Phase 4 | 28 |
Therapeutic Areas
What is open in the M.D. Anderson Cancer Center pipeline
549 recruiting of 2,692 indexed (20% open); 1,201 completed (45%).
Phase mix: 124 late (III/IV) vs 1,719 early (I/II) (early-phase heavy).
Top condition: Hematopoietic and Lymphoid Cell Neoplasm (44 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.